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Abstract 
 
Class I alcohol dehydrogenases (ADH1) are the rate-limiting enzymes for ethanol and vitamin A 
(retinol) metabolism in the liver. Since previous studies have shown that human ADH1 enzymes 
may participate in bile acid metabolism, we investigated whether the bile acid-activated nuclear 
receptor farnesoid X receptor (FXR) regulates ADH1 genes. In human hepatocytes, both the 
endogenous FXR ligand chenodeoxycholic acid (CDCA) and synthetic FXR-specific agonist 
GW4064 increased ADH1 mRNA, protein, and activity. Moreover, overexpression of a 
constitutively active form of FXR induced ADH1A and ADH1B expression, whereas silencing of 
FXR abolished the effects of FXR agonists on ADH1 expression and activity. Transient 
transfection studies and electrophoretic mobility shift assays revealed functional FXR response 
elements in the ADH1A and ADH1B proximal promoters, thus indicating that both genes are 
direct targets of FXR. These findings provide the first evidence for direct connection of bile acid 
signaling and alcohol metabolism. 
 
 
Supplementary key words: FXR; bile acids; ADH1; gene regulation; ethanol; liver 
metabolism 
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INTRODUCTION 
 
 Alcohol dehydrogenases (ADHs; EC 1.1.1.1) are enzymes able to reversibly oxidize of a 
wide variety of endogenous and xenobiotic alcohols to the corresponding aldehydes (1). 
Mammals have evolved different ADHs that can be grouped into five classes based on 
similarities in amino acid sequences and biochemical properties (2). Class I ADH (ADH1) 
constitutes the classical hepatic form that accounts for most of the ethanol-oxidizing capacity in 
the liver (3). Only one ADH1 enzyme and gene (Adh1) is found in the mouse and rat. By 
contrast, humans have three class I ADHs (ADH1A, ADH1B and ADH1C; traditionally 
designated , , and  isoenzymes, respectively) that are encoded by unique genes that are 
clustered head-to-tail within an 80 kb on chromosome 4 and are very similar to each other in the 
exon-intron structure and nucleotide sequences (1). All three human ADH1 enzymes are highly 
expressed in the adult liver and at lower levels in a variety of extrahepatic tissues (4). A different 
pattern of temporal expression for each of the three isoenzymes have been observed during liver 
development (4). Considerable efforts have been devoted to identify the factors involved in 
controlling human class I ADH gene expression, most of them focused on the analysis of tissue 
specific and temporal regulation. The three ADH1 genes share 80-84% sequence identity for 
about 270 bp upstream of the transcription start site, and significant similarity among them 
extends to -795 bp (5). However, in vitro binding analysis and transfection studies in liver and 
non-liver cancer cell lines revealed regulatory sequences mediating differential transcriptional 
mechanisms for each of the ADH1 genes to account for the distinct expression patterns (6). Thus, 
transcription factors CCAAT/enhancer-binding protein  (C/EBP), C/EBP and HNF-1 were 
found to selectively contribute to the liver specific expression and the induction of each of the 
ADH1 genes during liver development (7,8). 
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 Bile acids may function as signaling molecules in regulating their own synthesis and 
transport and controlling lipid and glucose homeostasis (9). Bile acid signaling in the liver is 
mostly mediated via the farnesoid X receptor  (FXR; NR1H4, hereafter referred as FXR), a 
member of the nuclear receptor superfamily of ligand-activated transcription factors (10). FXR 
heterodimerizes with the retinoid X receptor (RXR) and binds to consensus sequences, most 
commonly an IR1 (inverted hexameric nucleotide repeat separated by one nucleotide), and, in 
the presence of specific agonists, activates transcription of target genes involved in bile acid, 
cholesterol, lipoprotein, and glucose metabolism (10). FXR has been shown to have relevance in 
the attenuation of clinically important conditions such as gallstone disease (11,12), cholestasis 
(13), and fatty liver disease (14). Most of these hepatoprotective functions of FXR can be 
attributed to the induction of genes involved in bile acid detoxification and xenobiotic 
metabolism, including phase I oxidation enzyme CYP3A4 (15), and a number of phase II 
conjugation enzymes (16), and phase III efflux transporters (10). 
 In addition to the rate-limiting step in ethanol metabolism, human ADH1 isoenzymes 
catalyze steps in several metabolic pathways including vitamin A (retinol) oxidation, which is 
the rate-limiting step in the conversion of retinol to retinoic acid (17), and, interestingly, bile acid 
metabolism. Thus, ADH1B has been shown to oxidize the bile alcohol 5-cholestane-3, 7, 
12, 26-tetrol to the 3, 7, 12-trihydroxy-5-cholestanoic acid, an intermediate in bile acid 
synthesis (18), whereas ADH1C was identified as the sole bile acid 3-hydroxysteroid 
dehydrogenase present in human liver citosol that promotes epimerization of iso bile acids to 3-
hydroxy bile acids, which are subsequently secreted by hepatocytes into bile (19,20). In this 
study, we investigated the effect of both the endogenous bile acid chenodeoxycholic acid 
(CDCA) and synthetic FXR agonist GW4064 on class I ADH gene expression. The data 
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presented herein identify the nuclear receptor FXR as a regulator of human ADH1 genes, thus 
linking bile acid signaling and alcohol metabolism. 
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MATERIALS AND METHODS 
 
Animal Experiments 
 Experimental protocols with mice were performed with the approval of the animal ethics 
committee of the University of Barcelona (Spain). 10-week-old male C57BL/6 were injected 
intraperitoneally with either vehicle (corn oil 5% DMSO) or GW4064 (GlaxoSmithKline, RTP, 
NC) dissolved in vehicle (10 mg/ml) at a dose of 50 mg/kg. After 8 h, mice were sacrificed, and 
livers were excised, snap-frozen in liquid nitrogen, and stored at -80 ºC until analysis. 
 
Cell Culture and Treatment Conditions 
 Human hepatoma HepG2 and Huh7 cells and rat hepatoma FAO cells were cultured in 
DMEM supplemented 10% FBS. Primary mouse hepatocytes were isolated by the collagenase 
method as previously described (21) and cultured for 6 h before treatments. Human primary 
hepatocytes were obtained commercially (Ready HepsTM Fresh Hepatocytes, Lonza, Basel, 
Switzerland) and maintained in Hepatocyte Complete Medium (HCMTM bulletkit, Lonza). Cells 
were treated with ligands in the same medium supplemented with 10% charcoal stripped FBS 
(Biological Industries). 
 
RNA Isolation and Real-time Quantitative PCR Analysis 
 Total RNA was isolated from cells or livers by using Tri-Reagent (Ambion) and further 
treated with DNase I (Ambion). cDNA was synthesized from total RNA (1 g) by murine 
leukemia virus reverse transcriptase (Invitrogen) and p(dN)6 random primers (Roche 
Diagnostics) according to the manufacturer’s instructions. cDNA was subjected to real-time 
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quantitative PCR using Platinum® Quantitative PCR SuperMix-UDG with ROX (Invitrogen) and 
the specific TaqMan® Gene Expression Assay probes (Applied Biosystems): ADH1A, 
Hs00605167_g1; ADH1B, Hs00605175_m1; ADH1C, Hs00817827_m1; CYP2E1, 
Hs00559368_m1; ALDH1A, Hs00946916_m1; ALDH2 Hs00355914_m1; PLTP, 
Hs01067287_m1; NR0B2, Hs00222677_m1; NR1H4, Hs00231968_m1; mouse Adh1, 
Mm00507711_m1; mouse Nr0b2, Mm00442278_m1; rat Adh1, Rn00570670_m1; rat Nr0b2, 
Rn00589173_m1. Relative mRNA abundance was obtained by normalizing to 18S levels. 
 
Small Interfering RNA Transfection 
 The human FXR siGENOME SMARTpool (M-003414-01) or siGENOME Non-
Targeting siRNA #1 (D-001210-01) (Dharmacon, Lafayette, CO) were used to transfect Huh7 
cells with the DharmaFECT 4 Transfection Reagent at a final concentration of 25 nM each for 48 
h, followed by 24 h of treatments as described above. 
 
Adenoviral Infection 
 Huh7 cells were infected at a multiplicity of infection of 25 or 50 for 48 h with 
adenoviruses expressing VP16 (AdVP16) or VP16FXR chimeras (AdVP16FXR) previously 
described (22). 
 
Plasmids 
 The ADH1A proximal promoter (-1877 to +78 relative to the transcription start site) was 
amplified by PCR from genomic DNA using primers 5’-agtcacgcgtggagctaggtatagttgatg-3’ and 
5’-agtcctcgagtccttgtggatttcttcc-3’, MluI/XhoI digested, and subcloned into pGL3-basic vector 
(Promega) to generate pGL3-ADH1A. Similarly, the ADH1B promoter (-2850 to +59) was 
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amplified using primers 5’-agtcggtaccattattctgcctagcacacc-3’ and 5’-
agtcgctagcagactgtgagtctttgtgg-3’, while the ADH1C promoter (-2519 to +35) was amplified 
using primers 5’- agtcggtacctcgtactatccctgattgg-3’ and 5’- agtcgctagcttcttctctgcttgagtgc-3’, and 
the PCR products were subcloned into KpnI/NheI sites of the pGL3bv to generate pGL3-ADH1B 
and pGL3-ADH1C, respectively. Mutagenesis were performed using QuickChangeTM site-
directed mutagenesis kit (Stratagene) and oligonucleotides containing mutations corresponding, 
respectively, to nt -97A→G/-92C→G/-91C→G of ADH1A promoter, nt -120A→G/-115C→G/-
114C→G of ADH1B promoter, and nt -122G→A/-121G→T/-115A→T/-114T→C of ADH1C 
promoter. The reporter plasmids pADH1AIR1-TK, pADH1BIR1-TK, and pADH1CIR1-TK were 
generated by insertion of 4 copies of a double-stranded oligonucleotide containing sequences 
spanning nt -108 to -82 of ADHA1 (5’-gatccattgctggttcattgccctcttcttta-3’), nt -131 to -106 of 
ADH1B (5’-gatccattgctggttcagtacccttttatcta-3’), or nt -133 to -107 of ADH1C (5’-
gatccagtgctggttcggtgcccatttcttta-3’), into the BglII site of pGL3-TK (23). Plasmids expressing 
human retinoid X receptor  (RXR, NR2B1) and FXR into pSG5 have been described (23). 
 
Cell Transfection and Reporter Assays 
 Huh7 cells were transiently transfected as previously described (23). After 6h, cells were 
treated for 24 h with the vehicle (DMSO), 100 M CDCA, or 1 M GW4064 as described 
above. Luciferase activities were assayed as previously described (23). All transfections were 
performed in triplicate, and similar results were obtained in at least three independent 
experiments. 
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Western Blot Analysis 
 Whole protein cell extracts were obtained from Huh7 cells in Nonidet P-40 lysis buffer 
(150 mM NaCl, 50 mM Tris-HCl, 1% Nonidet P-40) supplemented with a mixture of protease 
inhibitors (Sigma Aldrich) and 0.1 mM phenylmethylsulfonyl fluoride (Sigma Aldrich). 50 g 
were resolved in 10% polyacrylamide gels, transferred onto Immobilon-P membranes (Millipore, 
Bedford, MA) and probed with antibodies: anti-pan ADH1 (1:200, Santa Cruz Biotechnology, 
Santa Cruz, CA, cat# sc-22750); anti-FXR (1:1000, Invitrogen, cat# A9033A); anti-actin 
(1:1000, Sigma Aldrich, cat# A2066). 
 
In Silico Analysis of FXR Response Elements (FXREs) 
 The analysis of genomic sequences for the identification of putative FXREs was 
performed using the NUBIScan computer algorithm (www.nubiscan.unibas.ch/). 
 
In Vitro Transcription/Translation and Electrophoretic Mobility Shift Assay (EMSA) 
 Double-stranded oligonucleotides corresponding to the sequences spanning nt -108 to -82 
of ADHA1, nt -131 to -106 of ADH1B, or nt -133 to -107 of ADH1C were radiolabeled and used 
in EMSA as previously described (23). A probe containing the FXRE of the human ileal-bile 
acid-binding protein (I-BABP) gene promoter was used as a control. For competition 
experiments, increasing fold molar excess of unlabeled probes were included during a 15 min 
preincubation on ice. The probe mutADH1AIR1 corresponds to the sequence spanning nt -108 to 
-82 of ADHA1 harboring mutations in nt -97A→G/-92C→G/-91C→G. 
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Alcohol Dehydrogenase Activity Assay 
 ADH enzymatic activity was determined using Alcohol Dehydrogenase Assay Kit (cat# 
K787, BioVision, Milpitas, CA) following manufacturer’s instruction, and normalized to protein 
content in each sample. 
 
Statistical Analysis 
 Data are expressed as mean ± SEM as determined by analysis of multiple independent 
samples, as indicated in figure legends. Significant differences were assessed using a two-tailed 
Student’s t test. Values of p < 0.05 were considered to be significant. 
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RESULTS 
 
Class I ADH Gene Expression is Induced in Human Primary Hepatocytes and Hepatoma 
Cell Lines in Response to FXR Ligands 
 Inasmuch as FXR regulates the expression of genes involved in detoxification and drug 
metabolism (15,16), and because class I ADH enzymes are reported to take part in bile acid 
metabolism (18-20), we evaluated whether this nuclear receptor modulates class I ADH gene 
expression. Human primary hepatocytes were exposed for 24 h to CDCA, a natural bile acid 
agonist of FXR, or GW4064, a synthetic and specific FXR agonist, and analyzed for the 
expression of the three ADH1 genes. As illustrated in Fig. 1A, both FXR ligands significantly 
increased ADH1A and ADH1B mRNA levels. As expected, the well characterized FXR target 
gene PLTP (24) was also induced when primary human hepatocytes were treated with FXR 
agonists. In contrast, ADH1C mRNA were not induced after activation of FXR (Fig. 1A). To 
confirm these results in human hepatoma cell lines, HepG2 cells were also incubated in the 
presence of vehicle (DMSO) or FXR agonists. Again, no significant induction of ADH1C was 
observed in response to FXR ligands, whereas ADH1A and ADH1B mRNA levels were strongly 
increased (Fig. 1B). In addition, FXR activation failed to induce cytochrome P450 2E1 
(CYP2E1), cytosolic aldehyde dehydrogenase (ALDH1A1), or mitochondrial aldehyde 
dehydrogenase (ALDH2) mRNA levels. Next, Western blot analyses performed on cell lysates 
from Huh7 treated with FXR agonists revealed that the quantity of ADH1 protein was robustly 
increased, compared to cells receiving vehicle (Fig. 1C). 
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Overexpression of Constitutively Active FXR Increases ADH1A and ADH1B mRNA Levels
 To further confirm the role of FXR in the regulation of the ADH1 gene cluster, we 
performed gain-of-function studies by ectopically expressing a constitutively active form of FXR 
(VP16FXR) (22) in Huh7 cells. The expression of ADH1A and ADH1B, but not ADH1C, was 
induced by FXR overexpression (Fig. 2). Collectively, these data suggest that FXR induces 
specifically the expression of ADH1A and ADH1B isoenzymes. 
 
The Inductions of ADH1A and ADH1B by CDCA and GW4064 Require FXR Expression
 Since bile acids may exert their signaling actions through FXR-independent pathways 
(9,25), we silenced FXR by siRNA to ascertain whether the inductions observed upon treatment 
with CDCA were dependent on FXR. Therefore, Huh7 were transfected with non-targeting 
siRNA or siRNA complexes directed against FXR (siFXR) before treatments. siFXR-mediated 
knock-down of endogenous FXR levels (Fig. 3A) almost completely eliminated the induction of 
ADH1A and ADH1B by bile acid CDCA (Fig. 3B). As a control, CDCA-dependent induction of 
NR0B2 (hereafter referred as SHP), a well known FXR target gene (10), was similarly attenuated 
in siFXR-transfected cells. Likewise, as depicted in Fig. 3C, we also confirmed by FXR knock-
down the requirement of FXR in the responses of these genes to GW4064 to rule out any effect 
of this synthetic ligand that could relate to weak agonistic effects on other receptors (26). 
 
FXR Regulation of Class I ADH Does Not Occur in Rodents 
 To examine whether FXR regulation of ADH1 also occurs in rodents, C57BL/6 mice 
were treated with either vehicle or FXR agonist GW4064 and analyzed for hepatic transcript 
levels. Unexpectedly, no significant change of Adh1 mRNA levels was observed following 
activation FXR, in spite of the marked induction of the known FXR target Shp (Fig. 4A). To 
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exclude the possibility that the dissimilar findings in human hepatocytes and in mouse liver were 
attributable to methodological differences, mouse primary hepatocytes were incubated in the 
presence of vehicle or GW4064. Again, Shp was highly induced after FXR activation, whereas 
no significant change was detected in Adh1 transcript levels (Fig. 4B). Likewise, analyses 
performed on rat hepatoma FAO cells treated with CDCA, GW4064, or vehicle showed 
induction of Shp in response to FXR ligands but no change in rat Adh1 transcript levels (Fig. 
4C). Taken together, these data indicate that induction of class I ADH genes by activation of 
FXR is species specific since it was observed in human but not in rodent-derived hepatocytes. 
 
Identification and Functional Characterization of Putative FXREs in the Promoters of 
ADH1 Genes 
 In order to determine whether FXR directly controls ADH1 expression and also with the 
aim to understand the molecular mechanisms involved in the differences observed in the FXR 
dependent regulation of the distinct human ADH1 genes, the promoters of ADH1A, ADH1B and 
ADH1C were in silico analyzed for putative FXREs using the NUBIScan computer algorithm. 
Most known FXREs consist of an IR of the RGGTCA hexad with minor variants (27,28). 
Accordingly, an IR1 motif was identified as a putative FXRE in the proximal promoter of each 
of the three genes. As illustrated in Fig. 5A, IR1 elements in ADH1A, ADH1B and ADH1C 
promoters differ from 2, 3 and 4 nucleotides, respectively, from the consensus FXRE. The 
presence of a T at position 3 and a C at position 10 of the IR1 element are permissive (e.g. 
FXREs of FGF19 and ALAS1, respectively) (10,29). In contrast, A into G conversion at the sixth 
position, as it occurs in the ADH1C element, is detrimental to receptor binding (27,28). To 
determine if the ADH1 proximal promoters were able to confer a response to FXR, we performed 
transient transfection assays in Huh7 cells with luciferase reporter constructs under the control of 
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~2-2.9 kb fragments corresponding to ADH1 gene promoters in the presence or absence of a 
plasmid encoding FXR and the agonist GW4064. The data in Fig. 5B show that reporter activity 
of ADH1A and ADH1B promoter constructs was increased by activated FXR, whereas no 
significant effects were observed on the ADH1C promoter construct or the promoterless pGL3 
basic vector. These results are consistent with the higher similarity of ADH1A and ADH1B IR1 
elements to the consensus FXRE. To further confirm this observation, the IR1 element for each 
promoter was cloned upstream of the thymidine kinase promoter-driven luciferase reporter gene. 
As expected, transient transfection assays showed that the reporter constructs containing the IR 
sequences of ADH1A or ADH1B, but not of ADH1C, were strongly transactivated by FXR (Fig. 
5C). 
 To assess the importance of the identified IR1 elements in FXR-dependent activation, we 
introduced single nucleotide mutations to disrupt the IR1 in the context of ADH1 promoters to 
generate pGL3-ADH1Amut and pGL3-ADH1Bmut constructs, respectively. As depicted in Fig 
5D, these point mutations completely abrogated the response to FXR. We next investigated the 
effects of performing site-directed mutations to convert the ADH1C IR1 element into the ADH1A 
IR1 element in the context of the of ~2.6 kb ADH1C promoter. In contrast to the wild-type, the 
activity of the construct bearing the mutated IR1 (pGL3-ADH1Cmut1A) was markedly increased 
by FXR (Fig. 5E). Collectively, these findings indicate that ADH1A and ADH1B are direct target 
genes of FXR and that the IR1 elements located at their respective proximal promoters are 
essential for the response to FXR. 
 
Binding Analysis of FXR to the IR1s in the ADH1A and ADH1B Promoters 
 To determine whether FXR-RXR heterodimers directly bind the IR1s identified in the 
proximal promoters of ADH1 genes, electrophoretic mobility shift analysis (EMSAs) were 
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performed. Incubation of in vitro translated FXR and RXR together with radiolabeled double-
stranded oligonucleotides containing the IR1 located at the proximal promoter of ADH1A or 
ADH1B resulted in a specific retarded complex (Fig. 6A, lanes 4 and 6, respectively). In contrast, 
the probe containing the IR1 in the ADH1C promoter failed to form a specific DNA protein 
complex (Fig. 6A, lane 8). The well characterized IR1 from ileal-bile acid-binding protein (I-
BABP) served as a positive control (Fig. 6A, lane 2) (30). As expected, more detailed gel-shift 
analyses demonstrated that FXR indeed binds as a heterodimer with RXR to these IR1s since the 
appearance of a robust retarded complex with ADH1AIR1 (Fig. 6B, lane 4) or ADH1BIR1 (data 
not shown) required the presence of both FXR and RXR proteins. The specificity of these 
complexes was demonstrated by successfully competition by increasing concentrations of either 
the unlabeled oligonucleotide dimers corresponding to the wild-type IR1, or I-BABP FXRE 
probes (Fig. 6B, lanes 5-7 and lanes 11-13), whereas no disappearance of the retarded complexes 
was appreciated when a mutated IR1 was used as a competitor (Fig. 6B, lanes 8-10). 
 
Activation of FXR Increases ADH1 Enzymatic Activity 
 Having shown that activation of FXR increases ADH1 mRNA and protein levels, we next 
investigated whether the activity of the enzyme was also increased. Exposure of Huh7 cells to 
CDCA or GW4064 resulted in an increase of alcohol dehydrogenase activity (Fig. 7A). To 
confirm that such increase was dependent on FXR, we transfected Huh7 cells with FXR-specific 
or non-targeting siRNA prior to treatments with GW4064. As depicted in Fig. 7B, when FXR 
expression was silenced, the stimulatory effect of GW4064 on ADH activity is completely 
abolished. Thus, we conclude that FXR regulates not only ADH1 expression but also the overall 
cellular ADH activity. 
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DISCUSSION 
 
 The present study identifies the human ADH1A and ADH1B genes as direct targets of the 
bile acid-activated nuclear receptor FXR. The evidences for this finding are the following: a) the 
expression of ADH1A and ADH1B is induced in HepG2 cells, Huh7 cells, and primary human 
hepatocytes in response to natural and synthetic FXR ligands; b) overexpression of constitutively 
active FXR augments ADH1A and ADH1B mRNA levels; c) IR1 elements identified at the 
proximal promoters of ADH1A and ADH1B are able to confer FXR response and bind FXR-RXR 
heterodimers; d) alcohol dehydrogenase activity is increased upon FXR activation; e) silencing 
of FXR abolished the effects of FXR agonists on ADH1 expression and activity. 
 At the present time, the reason why FXR regulates ADH1 genes is not immediately 
obvious. Previous studies have shown that 3-dehydrogenation of iso bile acids is catalyzed by 
ADH1C isoenzyme (19,20), yet we have failed to observe significant changes in ADH1C 
expression in response to FXR agonists. Moreover, although ADH1B has been shown to catalyze 
a step of bile acid synthesis (18), it is counterintuitive to presume that this is the explanation for 
the FXR-dependent regulation of ADH1B given the inhibitory effects that FXR exerts on the 
biosynthesis of bile acids (10). In fact, more recent reports have concluded that ADH1 activity 
may be dispensable for bile acid biosynthesis, since the bile acid pool is unchanged when class I 
ADH is absent (31), and that mitochondrial CYP27 performs all steps in the formation of 3, 7, 
12-trihydroxy-5-cholestanoic acid from the corresponding 3, 7, 12-triol (32,33). 
Nevertheless, given the bile acid detoxifying role of FXR (16), we cannot exclude that the 
regulation of ADH1 genes by FXR responds to protective pathways whereby ADH1A and 
ADH1B isoenzymes metabolize yet unknown bile alcohols and/or bile acids to less toxic 
products. In agreement with this hypothesis, several bile alcohols and bile acids that are 
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intermediates in the bile acid synthetic pathway have been identified as highly efficacious 
ligands for FXR (34). Also in this regard, it is interesting to consider the sequential turn-on of 
ADH1 genes during liver development. Whereas ADH1A isoenzyme is found during early stages 
of fetal liver development and ADH1B appears at later fetal stages, ADH1C is only detected 
several months postnatally (4). Therefore, it is tempting to speculate that the isoenzyme specific 
regulation by FXR that we observe may correspond to a mechanism of protection during fetal 
liver development. In this context, it is worth noting that fetal bile acid synthesis differs 
markedly from that of adult and “atypical” bile acids are found in human fetal bile. As an 
example, C-4 hydroxylated bile acids, which account for 5-15% of the total biliary bile acids of 
the fetus, are exclusive to early human development (35). Hence, it will be of considerable 
interest for future liver development studies to determine whether human ADH1 isoenzymes 
metabolize fetal specific bile acids. 
 Strikingly, the FXR-dependent induction of class I ADH1 genes is species-specific, 
because rodent hepatic Adh1 mRNA levels did not increase after activation of FXR (Fig. 4). 
Such a species-dependent regulation has also been observed for other human FXR target genes, 
including syndecan-1 (36), fibrinogen (37), A-crystallin (38), PPAR, hepatic lipase (40), 
ALAS1 (29), fetuin-b (41), and PCSK9 (42). The reason for such expansion in the repertoire of 
FXR targets in humans, compared to rodents, remains obscure. Probably, it is a reflection of 
species differences in bile acid composition as well as the novel roles that bile acids have 
acquired as signaling molecules in humans. Interestingly, a number of studies have focused on 
the evolutionary history of class I ADH in order to understand specific processes regarding 
primate adaptation to dietary alcohols (43). The three human ADH1 paralogs mainly originated 
from sequential duplications of an ancestral ADH1 gene after the divergence between rodents 
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and primates. Several lines of evidence indicate that the first split was between ADH1C and the 
gene that gave rise ADH1B and ADH1A (43). The current findings that FXR induces ADH1A and 
ADH1B but not ADH1C correlates with this evolutionary mechanism that places ADH1C as the 
outgroup. Consequently, it is tempting to postulate that the FXR response appeared after the first 
split and before the split between ADH1A and ADH1B. 
 Inasmuch as ADH1 enzymes catalyze the rate-limiting steps of retinol and ethanol 
metabolism in humans (3,17), the current data suggest that the activation of FXR is likely to 
enhance the metabolism of retinol and ethanol. On the other hand, we did not observe a 
significant effect of FXR activators in the mRNA levels of CYP2E1, an enzyme that also 
contributes to ethanol metabolism in chronic alcohol ingestion. In addition, incubation of human 
cells with FXR agonists failed to increase ALDH1A1 or ALDH2 mRNA levels. Therefore, 
additional studies will be required to define whether treatments with FXR ligands might 
effectively modify ethanol metabolism in vivo. 
 In conclusion, our data reveal a direct stimulatory role for FXR on ADH1, which points 
to a possible involvement of ADH1 in bile alcohol and/or bile acid catabolism. Furthermore, the 
FXR-dependent activation of ADH1 also suggest a potential effect on ethanol metabolism that 
should be taken into account in future clinical trials with FXR modulators. 
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FIGURE LEGENDS 
 
Fig. 1. Bile acids and synthetic FXR ligand GW4064 increase human ADH1 mRNA and protein 
levels. (A) Human primary hepatocytes and (B) HepG2 cells were incubated with vehicle 
(Control), 50 M CDCA, or 5 M GW4064 for 24 h. Total RNA was extracted and reverse 
transcribed for analysis by real time quantitative PCR (QPCR). Specific mRNA levels 
normalized to 18S content are expressed relative to control set as 1 (mean ± SEM). (C) Western 
blot analysis of total protein lysates from Huh7 cells treated as in (A). Protein signals were 
quantified and pan ADH1 levels were normalized to actin content. *, p < 0.05; **, p < 0.01; ***, 
p < 0.001 versus untreated controls. The results are representative of three independent 
experiments from triplicate dishes. 
 
Fig. 2. Constitutive active FXR induces ADH1A and ADH1B expression. Huh7 cells were 
infected with increasing multiplicity of infection (MOI) of adenovirus expressing either VP16 
(AdVP16) or a constitutively active chimera of VP16 and FXR (AdVP16FXR) for 48 h. Specific 
mRNA levels of ADH1A, ADH1B and ADH1C were determined by QPCR, normalized to 18S 
content and expressed relative to control set as 1 (mean ± SEM). *, p < 0.05; **, p < 0.01; ***, p 
< 0.001 versus 25 MOI AdVP16. The results are representative of two independent experiments 
from triplicate dishes. 
 
Fig. 3. The inductions of ADH1A and ADH1B expression by CDCA and GW4064 are FXR-
dependent. Huh7 cells were transfected with either control siRNA (siControl) or siRNA targeting 
FXR (siFXR). At 48 h post-transfection, cells were treated with vehicle (Control) (A-C), 50 M 
CDCA (B), or 5 M GW4064 (C) for 24 h. Specificity of the knockdown was checked by 
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determination of FXR protein levels by Western blot (A). Specific mRNA levels of SHP, 
ADH1A, ADH1B and were normalized to 18S content and expressed relative to values of mock-
transfected cells treated with vehicle set as 1 (mean ± SEM). *, p < 0.05; **, p < 0.01; ***, p < 
0.001 versus the corresponding controls. The results are representative of two independent 
experiments from triplicate dishes. 
 
Fig. 4. Induction of class I ADH by FXR does not occur in rodents. (A) C57BL/6 mice (n = 
5/group) were treated with either vehicle (Control) or 50 mg/kg GW4064 for 8 h. Adh1 and Shp 
expression was measured by QPCR in liver. (B) Primary mouse hepatocytes were incubated with 
vehicle (Control) or 5 M GW4064 for 24 h. (C) Rat hepatoma FAO cells were treated with 
vehicle (Control), 50 M CDCA, or 5 M GW4064 for 24 h. RNA was extracted and mRNA 
levels for Adh1 and Shp were determined. Specific Shp and Adh1 mRNA levels normalized to 
18S content are expressed relative to control set as 1 (mean ± SEM). **, p < 0.01; ***, p < 0.001 
versus untreated controls. 
 
Fig. 5. Characterization of a functional IR1 in the proximal promoter of ADH1A and ADH1B. 
(A) Schematic representation of human class I ADH gene cluster and localization of the IR1 
elements identified by NUBIScan in each proximal promoter. Alignment of the three IR1 and the 
FXRE consensus is shown below. The RGGTCA half-sites are indicated by arrows. (B) The 
promoters of ADH1A and ADH1B, but not of ADH1C, respond to activated FXR. Huh7 cells 
were transfected with a plasmid containing luciferase reporter constructs driven by ~2-2.9 kb 
fragments corresponding to ADH1 gene promoters (pGL3-ADH1A, pGL3-ADH1B, pGL3-
ADH1C, respectively), or the empty pGL3-basic vector as negative control, along with a plasmid 
26 
 
expressing FXR, or the empty expression vector pSG5 as control, and then treated for 24 h with 
vehicle (Control) or 1 M GW4064 and luciferase activities were measured. (C) IR1 elements in 
ADH1A and ADH1B, but not ADH1C, confer FXR responsiveness to a heterologous promoter. 
Experiments were performed as in (B) with reporter constructs containing four copies of the IR1 
site identified in the proximal promoter of ADH1 genes cloned in front of a heterologous 
thymidine kinase (TK) promoter-driven luciferase gene. pGL3-TK reporter vector was used as 
negative control. (D) Disruption of ADH1A and ADH1B IR1 elements by site-directed 
mutagenesis abrogates the response to FXR. Experiments were performed as in (B) with the 
indicated reporter constructs containing wild-type or IR1 mutated sequence. (E) Conversion of 
ADH1C IR1 to ADH1A IR1 element by site-directed mutagenesis confers FXR responsiveness to 
ADH1C promoter. Experiments were performed as in (B) with the constructs containing wild-
type ADH1C promoter or a modified version containing the IR1 converted to ADH1A IR1 
element. Results are expressed as -fold induction over control. ***, p < 0.001 versus untreated 
controls. The results are representative of three independent experiments from triplicate dishes. 
 
Fig. 6. The FXR/RXR heterodimer binds to the IR1 element in the proximal promoter of ADH1A 
and ADH1B. (A) EMSAs were performed using in vitro transcribed/translated FXR, RXR, or 
unprogrammed reticulocyte lysate (–), when indicated, and labeled double-stranded 
oligonucleotides containing the ADH1A, ADH1B or ADH1C IR1 element. Control, FXRE of I-
BABP. Note that the faint retarded bands of probe ADH1CIR1 (lanes 7 and 8) are nonspecific. 
The specific FXR-RXR-FXRE complex is indicated by an arrow. (B) EMSAs were performed 
as in (A) with a radiolabeled probe for ADH1A IR1 element. Competition experiments were 
performed by adding a 10-, 50-, and 250-fold molar excess of the indicated unlabeled probes. 
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Mutations present in the modified version of ADH1A IR1 (mutADH1AIR1) are shown in Fig. 
5D. Control, FXRE of I-BABP. 
 
Fig. 7. Activation of FXR increases ADH1 enzymatic activity. (A) FXR agonists increase ADH1 
activity. Huh7 cells were treated with vehicle (Control), 50 M CDCA, or 5 M GW4064 for 48 
h. Cells lysates were prepared and assayed for alcohol dehydrogenase activity as described in 
Materials and Methods. ***, p < 0.001 versus untreated control. (B) Knockdown of FXR 
abrogates the stimulatory effects of GW4064 treatment on ADH1 activity. Huh7 cells were 
transfected with either control siRNA (siControl) or siRNA targeting FXR (siFXR). At 48 h 
post-transfection, cells were treated with vehicle or 5 M GW4064 for 24 h, and ADH1 activity 
was determined. Values are normalized to protein content and expressed as mean ± SEM. **, p < 
0.01; ***, p < 0.001 versus untreated control. §§ < 0.01 versus siControl. The results are 
representative of at least two independent experiments from triplicate dishes. 
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